JP2002527356A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002527356A5 JP2002527356A5 JP2000559835A JP2000559835A JP2002527356A5 JP 2002527356 A5 JP2002527356 A5 JP 2002527356A5 JP 2000559835 A JP2000559835 A JP 2000559835A JP 2000559835 A JP2000559835 A JP 2000559835A JP 2002527356 A5 JP2002527356 A5 JP 2002527356A5
- Authority
- JP
- Japan
- Prior art keywords
- retinoid
- group
- vitamin
- composition
- analog
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 description 23
- 150000004492 retinoid derivatives Chemical class 0.000 description 21
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 16
- 229930003316 Vitamin D Natural products 0.000 description 15
- 235000019166 vitamin D Nutrition 0.000 description 15
- 239000011710 vitamin D Substances 0.000 description 15
- 150000003710 vitamin D derivatives Chemical class 0.000 description 15
- 229940046008 vitamin d Drugs 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 12
- 239000003814 drug Substances 0.000 description 10
- 201000004624 Dermatitis Diseases 0.000 description 6
- 201000004681 Psoriasis Diseases 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 208000010668 atopic eczema Diseases 0.000 description 6
- 150000001540 azides Chemical class 0.000 description 6
- 150000004820 halides Chemical class 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 125000003396 thiol group Chemical group [H]S* 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010020649 Hyperkeratosis Diseases 0.000 description 3
- 208000001126 Keratosis Diseases 0.000 description 3
- 206010051246 Photodermatosis Diseases 0.000 description 3
- 241001303601 Rosacea Species 0.000 description 3
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 3
- 206010040829 Skin discolouration Diseases 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 208000009621 actinic keratosis Diseases 0.000 description 3
- PLIUCYCUYQIBDZ-RMWYGNQTSA-N all-trans-4-oxoretinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)CCC1(C)C PLIUCYCUYQIBDZ-RMWYGNQTSA-N 0.000 description 3
- 229960002882 calcipotriol Drugs 0.000 description 3
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 3
- 229960005084 calcitriol Drugs 0.000 description 3
- 235000020964 calcitriol Nutrition 0.000 description 3
- 239000011612 calcitriol Substances 0.000 description 3
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000037336 dry skin Effects 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 206010021198 ichthyosis Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 201000004700 rosacea Diseases 0.000 description 3
- 208000008742 seborrheic dermatitis Diseases 0.000 description 3
- 230000037370 skin discoloration Effects 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- -1 4-oxo-retinyl ester Chemical compound 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- CYVVUYORRQQAQE-RMWYGNQTSA-N all-trans-4-hydroxyretinal Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(O)CCC1(C)C CYVVUYORRQQAQE-RMWYGNQTSA-N 0.000 description 1
- IOELQUUUYMBPSA-RMWYGNQTSA-N all-trans-4-hydroxyretinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(O)CCC1(C)C IOELQUUUYMBPSA-RMWYGNQTSA-N 0.000 description 1
- PLILDISEFZJECC-RMWYGNQTSA-N all-trans-4-oxoretinal Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)CCC1(C)C PLILDISEFZJECC-RMWYGNQTSA-N 0.000 description 1
- JWUBBDSIWDLEOM-DTOXIADCSA-N calcidiol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DTOXIADCSA-N 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- OVFMRFMJVFDSAA-UHFFFAOYSA-N propyl decanoate Chemical compound CCCCCCCCCC(=O)OCCC OVFMRFMJVFDSAA-UHFFFAOYSA-N 0.000 description 1
- 125000005323 thioketone group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 102000009310 vitamin D receptors Human genes 0.000 description 1
- 108050000156 vitamin D receptors Proteins 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/116,632 US20010002396A1 (en) | 1998-07-16 | 1998-07-16 | Compositions and methods of treating skin conditions |
| US09/116,632 | 1998-07-16 | ||
| PCT/US1999/015769 WO2000003700A1 (en) | 1998-07-16 | 1999-07-13 | Compositions and methods of treating abnormal cell proliferation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002527356A JP2002527356A (ja) | 2002-08-27 |
| JP2002527356A5 true JP2002527356A5 (https=) | 2006-09-28 |
Family
ID=22368338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000559835A Withdrawn JP2002527356A (ja) | 1998-07-16 | 1999-07-13 | 異常細胞増殖処置のための組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20010002396A1 (https=) |
| EP (1) | EP1104294B8 (https=) |
| JP (1) | JP2002527356A (https=) |
| AT (1) | ATE305296T1 (https=) |
| AU (1) | AU4988999A (https=) |
| CA (1) | CA2337138A1 (https=) |
| DE (1) | DE69927507T2 (https=) |
| DK (1) | DK1104294T3 (https=) |
| ES (1) | ES2249900T3 (https=) |
| MX (1) | MXPA01000492A (https=) |
| PT (1) | PT1104294E (https=) |
| WO (1) | WO2000003700A1 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6538037B2 (en) | 1991-01-08 | 2003-03-25 | Bone Care International, Inc. | Methods for preparation and use of 1α,24(S)-dihydroxyvitamin D2 |
| US5763429A (en) * | 1993-09-10 | 1998-06-09 | Bone Care International, Inc. | Method of treating prostatic diseases using active vitamin D analogues |
| US6242434B1 (en) * | 1997-08-08 | 2001-06-05 | Bone Care International, Inc. | 24-hydroxyvitamin D, analogs and uses thereof |
| US6503893B2 (en) | 1996-12-30 | 2003-01-07 | Bone Care International, Inc. | Method of treating hyperproliferative diseases using active vitamin D analogues |
| US20020128240A1 (en) * | 1996-12-30 | 2002-09-12 | Bone Care International, Inc. | Treatment of hyperproliferative diseases using active vitamin D analogues |
| US6566353B2 (en) | 1996-12-30 | 2003-05-20 | Bone Care International, Inc. | Method of treating malignancy associated hypercalcemia using active vitamin D analogues |
| US6573256B2 (en) | 1996-12-30 | 2003-06-03 | Bone Care International, Inc. | Method of inhibiting angiogenesis using active vitamin D analogues |
| US20030129194A1 (en) * | 1997-02-13 | 2003-07-10 | Bone Care International, Inc. | Targeted therapeutic delivery of vitamin D compounds |
| US6087350A (en) * | 1997-08-29 | 2000-07-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of pretreatment chemicals to enhance efficacy of cytotoxic agents |
| WO1999049870A1 (en) * | 1998-03-27 | 1999-10-07 | Oregon Health Sciences University | Vitamin d and its analogs in the treatment of tumors and other hyperproliferative disorders |
| US8263580B2 (en) * | 1998-09-11 | 2012-09-11 | Stiefel Research Australia Pty Ltd | Vitamin formulation |
| US20090098065A1 (en) * | 2000-01-11 | 2009-04-16 | Avikam Harel | Composition and methods for the treatment of skin disorders |
| DE10010814A1 (de) * | 2000-03-08 | 2001-09-13 | Basf Ag | Verwendung von 4-Oxoretinol und dessen Derivaten in kosmetischen Zubereitungen |
| EP1301479A2 (en) * | 2000-07-18 | 2003-04-16 | Bone Care International, Inc. | STABILIZED 1$g(a)-HYDROXY VITAMIN D |
| US6566399B2 (en) * | 2000-08-03 | 2003-05-20 | Byung-Moo Min | Inhibitor of replicative senescence of human keratinocytes containing retinoic acid as active ingredients |
| BR0214679A (pt) * | 2001-12-03 | 2004-12-14 | Novacea Inc | Composições farmacêuticas compreendendo compostos a base de vitamina d ativa |
| US20030143165A1 (en) * | 2002-01-25 | 2003-07-31 | Allan Evans | NSAID-containing topical formulations that demonstrate chemopreventive activity |
| US7273607B2 (en) * | 2002-07-01 | 2007-09-25 | Karl G. Schakel, legal representative | Health enhancement method |
| US20050026877A1 (en) * | 2002-12-03 | 2005-02-03 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
| RU2005127622A (ru) * | 2003-02-05 | 2006-01-20 | Галдерма Ресерч Энд Девелопмент, С.Н.С. (Fr) | Композиция типа обращенной эмульсии, содержащая по меньшей мере один активный агент, чувствительный к присутствию воды, и ее применение в косметике и дерматологии |
| CA2517256C (en) * | 2003-02-26 | 2013-04-30 | Sugen, Inc. | Aminoheteroaryl compounds as protein kinase inhibitors |
| CA2525987A1 (en) * | 2003-06-05 | 2005-01-06 | Charles Achkar | Methods of treating hyperproliferative cell disorders |
| US20060189586A1 (en) * | 2003-06-11 | 2006-08-24 | Cleland Jeffrey L | Pharmaceutical compositions comprising active vitamin D compounds |
| US20050020546A1 (en) * | 2003-06-11 | 2005-01-27 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
| FR2862540B1 (fr) * | 2003-11-21 | 2007-03-30 | Galderma Res & Dev | Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile |
| US8404667B2 (en) * | 2006-12-29 | 2013-03-26 | Wisconsin Alumni Research Foundation | Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog |
| FR2871699A1 (fr) * | 2004-06-17 | 2005-12-23 | Galderma Sa | Composition de type emulsion inverse contenant du calcitrol et du 17-propionate de clobetasol, et ses utilisations en cosmetiques et en dermatologie |
| US7094775B2 (en) * | 2004-06-30 | 2006-08-22 | Bone Care International, Llc | Method of treating breast cancer using a combination of vitamin D analogues and other agents |
| US20060003950A1 (en) * | 2004-06-30 | 2006-01-05 | Bone Care International, Inc. | Method of treating prostatic diseases using a combination of vitamin D analogues and other agents |
| US20060177390A1 (en) * | 2005-02-08 | 2006-08-10 | Person John R | Skin cancer prevention method and product |
| US20100093674A1 (en) * | 2005-08-04 | 2010-04-15 | Person John R | Skin cancer prevention method and product |
| US20060073107A1 (en) * | 2004-10-04 | 2006-04-06 | Person John R | Use of vitamin D3 (cholecalciferol) in sunscreens |
| DK1879595T3 (en) * | 2005-05-10 | 2015-01-05 | Dermipsor Ltd | Preparations and Methods for the Treatment of Hyperproliferative Epidermal Diseases |
| JP2008540513A (ja) * | 2005-05-10 | 2008-11-20 | ダーミプソル リミテッド | スキンケアのための組成物及び方法 |
| WO2006133828A1 (en) * | 2005-06-17 | 2006-12-21 | Dsm Ip Assets B.V. | Novel use 25-hydroxycholecalciferol in combination with uv-b screening agents |
| FR2894465B1 (fr) * | 2005-12-14 | 2010-09-10 | Fabre Pierre Dermo Cosmetique | Utilisation de composes polyinsatures en tant qu'agents blanchissants |
| US20080275128A1 (en) * | 2007-04-27 | 2008-11-06 | Elliott C Lasser | Compositions and methods for the treatment of inflammatory conditions |
| CN102655869B (zh) | 2009-08-14 | 2016-08-10 | 博格有限责任公司 | 用于治疗脱发的维生素d3及其类似物 |
| US8747818B1 (en) | 2011-02-07 | 2014-06-10 | Dennis Gross | Self-tanning compositions |
| WO2015164622A2 (en) * | 2014-04-23 | 2015-10-29 | The Regents Of The University Of California | Analogs of n-acetylglucosamine and uses thereof |
| KR20170007856A (ko) * | 2014-06-04 | 2017-01-20 | 아본느 인터내셔날, 엘엘씨 | 피부 관리용 활성 성분의 전달을 위한 투명한 조성물 및 방법 |
| WO2016040638A2 (en) | 2014-09-10 | 2016-03-17 | Washington University | Compositions and methods for treatment of pre-cancerous skin lesions |
| US11752156B2 (en) | 2018-03-07 | 2023-09-12 | Athenex HK Innovative Limited | Compositions and methods for treating hyperproliferative skin disorders |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5514672A (en) | 1981-02-17 | 1996-05-07 | Bazzano; Gail S. | Use of retinoids and compositions containing same for hair growth |
| WO1984002845A1 (en) * | 1983-01-21 | 1984-08-02 | Advanced Drug Tech | Vitamin-containing skin care ointment |
| US4866048A (en) * | 1985-08-02 | 1989-09-12 | Leo Pharmaceutical Products Ltd. | Novel vitamin D analogues |
| JPS6360910A (ja) | 1986-09-01 | 1988-03-17 | Shiseido Co Ltd | 皮膚外用剤 |
| US5763428A (en) * | 1990-09-21 | 1998-06-09 | Bone Care International, Inc. | Methods of treating skin disorders with novel 1a-hydroxy vitamin D4 compounds and derivatives thereof |
| GB9109733D0 (en) * | 1991-05-07 | 1991-06-26 | Unilever Plc | Cosmetic composition |
| TW272187B (https=) | 1992-05-20 | 1996-03-11 | Hoffmann La Roche | |
| US5547947A (en) * | 1993-03-11 | 1996-08-20 | Hoffmann-La Roche Inc. | Methods of treatment |
| FR2714595B1 (fr) | 1993-12-30 | 1996-02-02 | Oreal | Emulsion eau dans huile contenant du rétinol, son utilisation et son conditionnement. |
| DE69529043T2 (de) | 1994-09-30 | 2003-05-08 | L'oreal S.A., Paris | Verwendung von einem Agonisten eines mit einem Chloridkanal assozierten Rezeptors zur Behandlung von Hautfalten |
| US5786391A (en) | 1995-01-11 | 1998-07-28 | Cornell Research Foundation, Inc. | Regulating gene expression using retinoids with Ch2 OH or related groups at the side chain terminal position |
| FR2738745B1 (fr) | 1995-09-15 | 1997-10-24 | Cird Galderma | Nouvelles compositions a base d'un melange synergetique entre au moins un ligand de vdr et un retinoide, et leurs utilisations |
-
1998
- 1998-07-16 US US09/116,632 patent/US20010002396A1/en not_active Abandoned
-
1999
- 1999-07-12 US US09/351,020 patent/US6242435B1/en not_active Expired - Fee Related
- 1999-07-13 PT PT99933947T patent/PT1104294E/pt unknown
- 1999-07-13 CA CA002337138A patent/CA2337138A1/en not_active Abandoned
- 1999-07-13 EP EP99933947A patent/EP1104294B8/en not_active Expired - Lifetime
- 1999-07-13 MX MXPA01000492A patent/MXPA01000492A/es active IP Right Grant
- 1999-07-13 ES ES99933947T patent/ES2249900T3/es not_active Expired - Lifetime
- 1999-07-13 WO PCT/US1999/015769 patent/WO2000003700A1/en not_active Ceased
- 1999-07-13 DK DK99933947T patent/DK1104294T3/da active
- 1999-07-13 DE DE69927507T patent/DE69927507T2/de not_active Expired - Fee Related
- 1999-07-13 AT AT99933947T patent/ATE305296T1/de not_active IP Right Cessation
- 1999-07-13 JP JP2000559835A patent/JP2002527356A/ja not_active Withdrawn
- 1999-07-13 AU AU49889/99A patent/AU4988999A/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002527356A5 (https=) | ||
| US6566352B1 (en) | 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses | |
| US7534778B2 (en) | (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses | |
| JP6189037B2 (ja) | 治療用ビタミンｄ日焼け止め製剤およびそれを使用するための方法 | |
| CN1501803A (zh) | 2α－甲基－19－去甲－20(S)－1α,25－二羟维生素D3增加骨强度的用途 | |
| CZ372892A3 (en) | Pharmaceutical preparation | |
| JP2006524659A (ja) | ケラチノサイトの過剰増殖、特に、アトピー性皮膚炎および乾癬を特徴とする疾患を治療するためのリルゾールの使用 | |
| WO2008127459A1 (en) | Pharmacological treatment of psoriasis | |
| IL133976A (en) | Agents for the treatment of skin disorders | |
| KR20120107963A (ko) | 담체 조성물 | |
| JPH092972A (ja) | Ｒｘｒ受容体に対して特異的なリガンドを含む製薬組成物 | |
| EP1722856B1 (en) | Use of 2-methylene-19-nor-20(s)-1alpha,25-dihydroxyvitamin d3 for the prophylaxis of bone diseases | |
| EP4357345A1 (en) | Cly series compound, preparation method therefor and use thereof in preparation of drugs | |
| US20160220589A1 (en) | Compositions and methods for the treatment of skin disorders | |
| CN107427488A (zh) | 鞣花酸二水合物在食品和保健品中的用途 | |
| JP2002537222A (ja) | カルセミック活性を持つ１９−ノル−ビタミンｄ３化合物 | |
| JPH05503922A (ja) | 創傷及び潰瘍の治癒の促進並びに歯周病の処置方法 | |
| CN112007039B (zh) | 一种包含氟西汀和维生素d3或其衍生物的组合物，及其应用 | |
| US10653659B2 (en) | Compositions comprising a compound from the family of avermectins and an agonist compound for at least one of the retinoic acid receptors for treating acne | |
| CN117959290B (zh) | N-苄基-5/6-甲酰氨基吲哚-2-羧酸衍生物在制备防治多囊卵巢综合征药物的应用 | |
| Bhuiyan et al. | Acitretin in dermatology a review | |
| EP1891960B1 (en) | Pharmaceutical formula for treating skin disease | |
| EP1552837A1 (en) | Antipsoriatic agent | |
| AU2002360534B2 (en) | 1-alpha-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses | |
| TW389693B (en) | Pharmaceutical composition for inhibiting skin and vagina atrophy |